Track record

Every buy, sell, and watch call Biotech Distilled has published — scored against XBI, the biotech index.

+249.3%Best call · ETON
-9.9%Avg buy call
75%Avoids beat XBI
122Active buy calls

As of Nov 17, 2026 · hypothetical editorial record, not investment advice

How to read this page
Buy
A buy call I published — Core = higher conviction.
Spec buy
A speculative buy — higher risk, smaller-size idea.
Avoid
A call to stay away — scored by the loss it sidestepped.
Buy▵
Conviction changed since the call opened — e.g. opened as a Spec buy, now a Buy. The badge shows today's conviction; the linked post is the opening call. Hover the badge for the date it changed.
Entry
The first closing price after I published the call — if I posted after the 4pm ET close, that's the next session's close, since it's the first price you could actually have traded at.
Now
The latest available closing price — on a closed call, the price it exited at, not today's price.
Return
Percent change from Entry to Now. Read it with the call type: on a buy, higher is better; on an avoid it is the stock's move, so a big positive number means the avoid was wrong. vs XBI is the column that scores every call the same way.
vs XBI
XBI is the biotech index ETF. This is Return minus XBI's return over the same dates — the value added beyond just buying the index. For avoids, the loss saved vs holding XBI.
Dates
Opened and Closed are the market sessions the call was priced at, which is usually the session after the post — a call published after the 4pm ET bell on a Friday prices on Monday. Hover a date to see which post it came from.
Open / Closed
Open = still live. Closed = realized; the return runs to the first close after I flipped the call. Where a buyout settled at a known cash price, I use that instead.

Top buy calls

CallBuyNowReturnvs XBI
ETON Eton Pharmaceuticals Buy $18.22 $63.65 +249.3% +234.7
SYRE Spyre Therapeutics Buy $33.47 $93.81 +180.3% +158.8
XERS Xeris Biopharma Spec buy $7.93 $16.80 +111.9% +119.5
REPL Replimune Group Buy $9.00 $19.69 +118.8% +109.9
CAPR Capricor Therapeutics Spec buy $4.17 $8.41 +101.7% +106
DRTS Alpha Tau Medical Spec buy $5.90 $12.09 +104.9% +90
DFTX Definium Therapeutics Buy $15.02 $29.38 +95.6% +81
LQDA Liquidia Spec buy $33.94 $56.73 +67.1% +68.2
XNCR Xencor Buy $21.49 $34.50 +60.5% +64.6
EXEL Exelixis Spec buy $41.36 $68.50 +65.6% +49.2

What I told you to avoid

CallSinceStockSaved vs XBI
RVPH Reviva Pharmaceuticals Avoid Jan 26, 2026 -94.1% +107.9
APVO Aptevo Therapeutics Avoid Jun 16, 2026 -89.8% +97.2
NRSN NeuroSense Therapeutics Avoid Jul 13, 2026 -89.7% +83.2
LGVN Longeveron Avoid May 11, 2026 -74.8% +82.6
ACTU Actuate Therapeutics Avoid Jul 20, 2026 -82% +78.3
IXHL Incannex Healthcare Avoid Mar 16, 2026 -47.4% +64.7
OTLK Outlook Therapeutics Avoid Jul 27, 2026 -66.1% +62.6
MRKR Marker Therapeutics Avoid Mar 16, 2026 -40.4% +57.7

Calls that paid off

Buy calls I closed in the green — including takeouts. Entry → exit, realized.

CallBoughtExitedReturnvs XBI
FBRX Forte Biosciences Acquired Apr 6, 2026 Jul 28, 2026 +189.9% +173.6
CRNX Crinetics Pharmaceuticals Acquired Apr 2, 2026 Jul 7, 2026 +124.4% +97.3
ATAI Atai Beckley Acquired Dec 24, 2025 Jul 17, 2026 +72.3% +50.2
APGE Apogee Therapeutics Acquired May 5, 2026 Jun 23, 2026 +59.5% +49.6
CNTA Centessa Pharmaceuticals plc Acquired Mar 16, 2026 Jun 23, 2026 +43.2% +24.4
QURE uniQure Spec buy Jun 18, 2026 Jun 23, 2026 +5.9% +1.4
ENTA Enanta Pharmaceuticals Buy Feb 17, 2026 Jul 6, 2026 +4.7% -24.5

Every call

Call Entry Now Return vs XBI Status Opened
ETON Eton Pharmaceuticals Buy $18.22 $63.65 +249.3% +234.7 Open Feb 19, 2026
FBRX Forte Biosciences Buy▵ $26.44 $76.65 +189.9% +173.6 Closed Jul 28, 2026 Apr 6, 2026
SYRE Spyre Therapeutics Buy $33.47 $93.81 +180.3% +158.8 Open Dec 18, 2025
XERS Xeris Biopharma Spec buy $7.93 $16.80 +111.9% +119.5 Open Aug 7, 2026
REPL Replimune Group Buy▵ $9.00 $19.69 +118.8% +109.9 Open Jun 1, 2026
RVPH Reviva Pharmaceuticals Avoid $6.04 $0.35 -94.1% +107.9 Open Jan 26, 2026
CAPR Capricor Therapeutics Spec buy $4.17 $8.41 +101.7% +106 Open Aug 4, 2026
CRNX Crinetics Pharmaceuticals Buy $37.23 $83.53 +124.4% +97.3 Closed Jul 7, 2026 Apr 2, 2026
APVO Aptevo Therapeutics Avoid $4.54 $0.46 -89.8% +97.2 Open Jun 16, 2026
DRTS Alpha Tau Medical Spec buy $5.90 $12.09 +104.9% +90 Open Jan 7, 2026
GOSS Gossamer Bio Avoid $34.29 $14.00 -59.2% +88.9 Closed Aug 24, 2026 Mar 2, 2026
NRSN NeuroSense Therapeutics Avoid $14.60 $1.51 -89.7% +83.2 Open Jul 13, 2026
LGVN Longeveron Avoid $8.38 $2.11 -74.8% +82.6 Open May 11, 2026
DFTX Definium Therapeutics Buy $15.02 $29.38 +95.6% +81 Open Jan 14, 2026
ACTU Actuate Therapeutics Avoid $1.40 $0.25 -82% +78.3 Open Jul 20, 2026
LQDA Liquidia Spec buy $33.94 $56.73 +67.1% +68.2 Open Oct 14, 2026
IXHL Incannex Healthcare Avoid $3.31 $1.74 -47.4% +64.7 Open Mar 16, 2026
XNCR Xencor Buy▵ $21.49 $34.50 +60.5% +64.6 Open Jul 30, 2026
OTLK Outlook Therapeutics Avoid $1.06 $0.36 -66.1% +62.6 Open Jul 27, 2026
ACTU Actuate Therapeutics Avoid $6.49 $2.89 -55.5% +62.2 Closed May 12, 2026 Jan 7, 2026
VNDA Vanda Pharmaceuticals Avoid $6.20 $4.00 -35.5% +61.9 Closed Oct 28, 2026 Feb 17, 2026
MRKR Marker Therapeutics Avoid $1.41 $0.84 -40.4% +57.7 Open Mar 16, 2026
KAPA Kairos Pharma Avoid $2.17 $0.87 -59.9% +53.7 Closed Oct 7, 2026 Aug 18, 2026
PHIO Phio Pharmaceuticals Avoid $1.32 $0.72 -45.7% +52.2 Open Apr 15, 2026
ATAI Atai Beckley Spec buy $4.19 $7.22 +72.3% +50.2 Closed Jul 17, 2026 Dec 24, 2025
APGE Apogee Therapeutics Buy $83.29 $132.88 +59.5% +49.6 Closed Jun 23, 2026 May 5, 2026
EXEL Exelixis Spec buy▵ $41.36 $68.50 +65.6% +49.2 Open Jan 30, 2026
ELTX Elicio Therapeutics Avoid $3.29 $1.43 -56.6% +46.9 Open Jul 6, 2026
EVMN Evommune Avoid $13.29 $6.92 -47.9% +45.5 Closed Oct 2, 2026 Jun 30, 2026
ORKA Oruka Therapeutics Buy $63.18 $96.32 +52.5% +45.5 Open May 13, 2026
CING Cingulate Avoid $5.84 $5.09 -12.8% +45.4 Closed Aug 14, 2026 Mar 30, 2026
PYPD PolyPid Spec buy $4.78 $6.54 +36.8% +44.2 Open Aug 13, 2026
PEPG PepGen Buy▵ $2.85 $3.88 +36.1% +43.8 Open Aug 7, 2026
PCSA Processa Pharmaceuticals Avoid $2.87 $2.04 -28.9% +43.6 Closed Jul 30, 2026 Apr 13, 2026
ONCY Oncolytics Biotech Avoid $0.77 $0.38 -50.6% +42.5 Open Sep 17, 2026
CMPX Compass Therapeutics Avoid $1.17 $0.61 -48.1% +41.7 Open Sep 23, 2026
IBRX ImmunityBio Buy▵ $3.95 $6.26 +58.5% +41.5 Open Jan 15, 2026
CRBU Caribou Biosciences Avoid $0.62 $0.34 -44.7% +41.4 Open Oct 7, 2026
BMEA Biomea Fusion Avoid $0.84 $0.49 -41.6% +38.6 Open Oct 15, 2026
TLSA Tiziana Life Sciences Avoid $1.11 $0.65 -41.4% +37.7 Open Oct 6, 2026
IVVD Invivyd Avoid $0.96 $0.51 -46.8% +36.5 Open Sep 22, 2026
ALDX Aldeyra Therapeutics Avoid $1.23 $0.69 -43.6% +35.7 Open Sep 30, 2026
PTN Palatin Technologies Avoid $9.12 $5.36 -41.2% +33.9 Open Sep 29, 2026
CGON CG Oncology Buy $53.81 $78.94 +46.7% +33.2 Open Jan 23, 2026
MBRX Moleculin Biotech Avoid $11.34 $6.83 -39.8% +32.9 Open Sep 24, 2026
SION Sionna Therapeutics Avoid $5.10 $3.07 -39.8% +31.7 Open Aug 11, 2026
FATE Fate Therapeutics Avoid $1.61 $1.02 -36.6% +29.6 Open Nov 11, 2026
KYMR Kymera Therapeutics Buy $87.35 $121.52 +39.1% +28.9 Open Apr 9, 2026
COYA Coya Therapeutics Avoid $4.34 $3.02 -30.4% +27.4 Open Oct 15, 2026
GANX Gain Therapeutics Avoid $1.71 $1.18 -31% +25.1 Open Oct 2, 2026
CNTA Centessa Pharmaceuticals plc Buy $28.29 $40.50 +43.2% +24.4 Closed Jun 23, 2026 Mar 16, 2026
EYPT EyePoint Avoid $0.41 $0.30 -26.8% +21.6 Open Oct 20, 2026
HURA TuHURA Biosciences Avoid $1.81 $1.40 -22.7% +21.6 Open Oct 13, 2026
TVTX Travere Therapeutics Buy $40.29 $51.10 +26.8% +21.4 Open Apr 20, 2026
KPRX Kiora Pharmaceuticals Avoid $1.23 $0.93 -24.4% +20.9 Open Nov 13, 2026
ABSI Absci Buy▵ $5.90 $7.58 +28.5% +20.6 Open May 8, 2026
ZURA Zura Bio Avoid $1.41 $1.03 -26.3% +20 Open Nov 10, 2026
TTRX Turn Therapeutics Spec buy $6.42 $8.55 +33.2% +19.5 Open Jun 2, 2026
CHRS Coherus Oncology Avoid $0.64 $0.48 -25.3% +19 Open Nov 10, 2026
MDNAF Medicenna Therapeutics Avoid $0.40 $0.32 -20% +17.6 Closed May 20, 2026 May 14, 2026
VSTM Verastem Buy▵ $6.74 $7.41 +9.9% +17.6 Open Aug 7, 2026
ZYME Zymeworks Buy▵ $23.54 $25.84 +9.8% +17.5 Open Aug 7, 2026
HELP Helus Pharma Spec buy $6.61 $7.20 +8.9% +17.1 Open Jun 30, 2026
CLRB Cellectar Biosciences Avoid $1.21 $0.92 -24% +16.9 Open Nov 11, 2026
HELP Helus Pharma Avoid $5.52 $4.32 -21.7% +15.2 Closed Mar 30, 2026 Mar 9, 2026
IRD Opus Genetics Spec buy $3.71 $4.05 +9.2% +13.5 Open Aug 4, 2026
IMVT Immunovant Buy $26.08 $33.21 +27.3% +13.3 Open Feb 2, 2026
UNCY Unicycive Therapeutics Avoid $5.13 $4.70 -8.5% +13.3 Closed Sep 30, 2026 Jul 27, 2026
VOR Vor Biopharma Spec buy $14.63 $18.18 +24.3% +13.1 Open May 15, 2026
ARDX Ardelyx Avoid $4.00 $3.18 -20.5% +12.8 Open Aug 7, 2026
CYDY CytoDyn Avoid $0.37 $0.32 -13.5% +11.1 Closed Apr 27, 2026 Apr 21, 2026
OVID Ovid Therapeutics Spec buy $1.81 $2.22 +22.7% +9.6 Open Jan 27, 2026
CADL Candel Therapeutics Avoid $6.20 $5.40 -12.9% +9.4 Open Nov 13, 2026
MESO Mesoblast Avoid $13.27 $11.91 -10.2% +6.7 Open Nov 13, 2026
BCTX BriaCell Therapeutics Avoid $3.31 $3.51 +6% +5.9 Open Jun 3, 2026
PMVP PMV Pharmaceuticals Spec buy $1.29 $1.22 -5.4% +5.7 Open Sep 1, 2026
OCGN Ocugen Avoid $0.78 $0.76 -2.9% +3.6 Open Oct 16, 2026
FHTX Foghorn Therapeutics Avoid $2.02 $1.83 -9.4% +3.5 Open Oct 2, 2026
OLMA Olema Pharmaceuticals Avoid $8.04 $7.22 -10.2% +3.1 Open Nov 11, 2026
CRVO CervoMed Avoid $2.44 $2.86 +17.2% +2 Closed Aug 10, 2026 Jun 11, 2026
ARTV Artiva Biotherapeutics Avoid $4.28 $3.86 -9.7% +1.9 Open Oct 28, 2026
IMUX Immunic Spec buy $7.23 $7.33 +1.4% +1.8 Open Nov 16, 2026
SGMT Sagimet Biosciences Spec buy $8.75 $9.85 +12.6% +1.8 Open Apr 28, 2026
ZBIO Zenas BioPharma Spec buy $29.51 $27.75 -6% +1.7 Open Aug 14, 2026
IRON Disc Medicine Buy $79.48 $76.57 -3.7% +1.5 Open Oct 20, 2026
GRCE Grace Therapeutics Avoid $2.16 $2.10 -2.8% +1.4 Closed Apr 28, 2026 Apr 27, 2026
QURE uniQure Spec buy $46.29 $49.04 +5.9% +1.4 Closed Jun 23, 2026 Jun 18, 2026
KAPA Kairos Pharma Avoid $0.41 $0.40 -1.7% +1.3 Open Nov 16, 2026
SPRB Spruce Biosciences Buy▵ $41.60 $40.49 -2.7% +0.3 Open Jul 28, 2026
GHRS GH Research Buy▵ $15.75 $18.27 +16% 0 Open Jan 20, 2026
CNTB Connect Biopharma Avoid $0.58 $0.58 0% 0 Open Nov 17, 2026
ABOS Acumen Pharmaceuticals Avoid $0.24 $0.23 -4.2% -0.3 Open Nov 2, 2026
AARD Aardvark Therapeutics Avoid $1.20 $1.15 -4.2% -0.3 Open Nov 2, 2026
NKTX Nkarta Spec buy $1.35 $1.25 -7.4% -1.1 Open Nov 10, 2026
CLYM Climb Bio Buy▵ $8.78 $9.78 +11.4% -1.3 Open Apr 29, 2026
IMNM Immunome Spec buy $17.91 $17.18 -4% -1.9 Open Nov 5, 2026
IONS Ionis Pharmaceuticals Avoid $28.19 $26.96 -4.4% -1.9 Open Nov 10, 2026
RYTM Rhythm Pharmaceuticals Buy $102.59 $116.61 +13.7% -2.3 Open Jan 20, 2026
BLTE Belite Bio Spec buy $178.94 $157.72 -11.9% -3 Open Aug 12, 2026
HROW Harrow Avoid $30.36 $29.52 -2.8% -3.5 Open Nov 10, 2026
AXSM Axsome Therapeutics Avoid $139.61 $135.95 -2.6% -3.6 Open Nov 3, 2026
AKBA Akebia Therapeutics Avoid $0.40 $0.40 -0.2% -4.3 Closed Nov 17, 2026 Nov 6, 2026
CRDL Cardiol Therapeutics Avoid $1.01 $0.97 -3.8% -4.9 Open Nov 4, 2026
PTGX Protagonist Therapeutics Buy $147.75 $124.67 -15.6% -5 Open Aug 31, 2026
IMCR Immunocore Spec buy $32.00 $27.81 -13.1% -5.8 Open Sep 18, 2026
GERN Geron Avoid $0.95 $0.95 0% -6 Closed Nov 5, 2026 Oct 29, 2026
RVMD Revolution Medicines Buy $177.65 $162.69 -8.4% -6.3 Open Nov 5, 2026
FBIO Fortress Biotech Avoid $1.71 $1.82 +6.4% -6.8 Open Nov 16, 2026
PCVX Vaxcyte Buy $66.70 $59.40 -10.9% -7.2 Open Oct 6, 2026
CMMB Chemomab Therapeutics Avoid $1.64 $1.64 0% -7.2 Open Sep 28, 2026
TENX Tenax Therapeutics Avoid $1.62 $1.80 +11.1% -7.7 Closed Sep 1, 2026 Aug 11, 2026
BEAM Beam Therapeutics Spec buy $25.18 $20.65 -18% -9.1 Open Sep 9, 2026
CBIO Crescent Biopharma Buy $15.11 $13.04 -13.7% -9.3 Open Jul 16, 2026
GUTS Fractyl Health Avoid $0.90 $0.96 +6.7% -10.2 Open Nov 13, 2026
PCSA Processa Pharmaceuticals Spec buy $2.04 $1.73 -15.2% -11.1 Open Jul 30, 2026
CRVO CervoMed Avoid $1.43 $1.50 +4.9% -12.3 Open Nov 9, 2026
CMPS COMPASS Pathways Buy $7.85 $7.98 +1.7% -12.8 Open Feb 23, 2026
GRCE Grace Therapeutics Spec buy $2.12 $1.72 -18.9% -12.9 Open Aug 6, 2026
LEGN Legend Biotech Spec buy $20.65 $16.11 -22% -13.1 Open Aug 12, 2026
MIST Milestone Pharmaceuticals Avoid $0.36 $0.41 +13.2% -13.6 Open Nov 16, 2026
ADMA Adma Biologics Avoid $9.16 $10.06 +9.8% -13.7 Closed Aug 6, 2026 Jul 6, 2026
VIR Vir Biotechnology Buy $8.99 $9.25 +2.9% -14.3 Open Mar 25, 2026
AMLX Amylyx Pharmaceuticals Spec buy $38.60 $27.52 -28.7% -14.4 Open Aug 19, 2026
LGVN Longeveron Spec buy $8.88 $8.38 -5.6% -14.4 Closed May 11, 2026 Mar 16, 2026
SABS SAB Biotherapeutics Spec buy $3.67 $2.95 -19.5% -15.1 Open Jul 16, 2026
ARVN Arvinas Spec buy $8.40 $7.42 -11.7% -15.6 Closed Nov 4, 2026 Aug 5, 2026
BCTX BriaCell Therapeutics Spec buy $4.47 $3.76 -15.9% -15.6 Closed Feb 23, 2026 Feb 2, 2026
ADCT ADC Therapeutics Spec buy $1.64 $1.35 -17.7% -15.6 Open Nov 5, 2026
VRDN Viridian Therapeutics Buy $29.17 $30.06 +3.1% -17.3 Open Feb 5, 2026
HELP Helus Pharma Spec buy $6.73 $5.52 -18% -18.1 Closed Mar 9, 2026 Feb 23, 2026
SLDB Solid Biosciences Spec buy $8.39 $6.23 -25.7% -18.1 Open Aug 7, 2026
NGNE Neurogene Spec buy $31.45 $23.10 -26.6% -18.4 Open Jun 30, 2026
ALLO Allogene Therapeutics Spec buy $2.25 $2.07 -8% -18.5 Closed Jun 23, 2026 Apr 27, 2026
NVCT Nuvectis Pharma Spec buy $24.48 $19.20 -21.6% -18.6 Open Jun 24, 2026
TNGX Tango Therapeutics Buy▵ $24.87 $22.11 -11.1% -18.8 Open May 14, 2026
DYN Dyne Therapeutics Buy $16.58 $16.02 -3.4% -19.3 Open Jan 20, 2026
RNAC Cartesian Therapeutics Buy $6.93 $6.12 -11.7% -19.7 Open May 27, 2026
NRIX Nurix Therapeutics Buy $15.91 $14.24 -10.5% -20.5 Open Apr 13, 2026
BMEA Biomea Fusion Spec buy $1.53 $1.49 -2.6% -21.6 Closed Sep 24, 2026 Apr 28, 2026
LENZ LENZ Therapeutics Spec buy $5.04 $3.50 -30.6% -21.7 Open Aug 12, 2026
ARTV Artiva Biotherapeutics Spec buy $10.60 $7.84 -26% -23.7 Closed May 20, 2026 May 11, 2026
CLDX Celldex Therapeutics Buy $33.86 $28.04 -17.2% -24.4 Open Apr 16, 2026
ENTA Enanta Pharmaceuticals Buy▵ $13.86 $14.51 +4.7% -24.5 Closed Jul 6, 2026 Feb 17, 2026
ERAS Erasca Spec buy $11.56 $9.11 -21.2% -24.6 Closed Apr 29, 2026 Feb 11, 2026
CYDY CytoDyn Avoid $0.22 $0.25 +13.6% -24.7 Open Sep 1, 2026
AKTS Aktis Oncology Buy▵ $19.73 $16.31 -17.3% -25 Open May 12, 2026
CRVS Corvus Pharmaceuticals Buy $11.50 $10.17 -11.6% -26.1 Open May 19, 2026
FBIO Fortress Biotech Spec buy $2.30 $2.03 -11.7% -26.3 Closed Oct 2, 2026 May 14, 2026
CRDL Cardiol Therapeutics Spec buy $1.02 $1.01 -1% -26.7 Closed Nov 4, 2026 Mar 2, 2026
MAIA MAIA Biotechnology Spec buy $1.31 $1.25 -4.6% -26.9 Open Mar 30, 2026
JBIO Jade Biosciences Spec buy $17.75 $15.40 -13.2% -27 Open Jun 2, 2026
ENTA Enanta Pharmaceuticals Spec buy $13.50 $8.69 -35.6% -27.5 Closed Nov 17, 2026 Aug 12, 2026
OMER Omeros Buy $15.71 $13.92 -11.4% -27.6 Open Dec 26, 2025
INBX Inhibrx Biosciences Spec buy $122.26 $74.18 -39.3% -27.7 Open Sep 3, 2026
VERA Vera Therapeutics Buy $31.27 $26.20 -16.2% -28.1 Open Jun 3, 2026
NRXP NRX Pharmaceuticals Spec buy $3.03 $2.45 -19.1% -28.3 Open Apr 27, 2026
DTIL Precision Biosciences Spec buy $10.60 $7.05 -33.5% -28.9 Open Nov 6, 2026
GLSI Greenwich LifeSciences Spec buy $22.25 $18.70 -16% -29 Closed Nov 17, 2026 Jun 5, 2026
RARE Ultragenyx Pharmaceutical Buy▵ $26.86 $16.70 -37.8% -29 Open Aug 12, 2026
KURA Kura Oncology Buy $9.22 $7.49 -18.8% -29.9 Open May 15, 2026
COGT Cogent Biosciences Buy $37.00 $27.85 -24.7% -30.2 Open Apr 20, 2026
CBIO Crescent Biopharma Buy $18.52 $15.67 -15.4% -31.3 Closed Jul 15, 2026 May 11, 2026
OCS Oculis Holding Spec buy $11.99 $7.51 -37.4% -33 Open Aug 4, 2026
PRQR ProQR Therapeutics Spec buy $1.94 $1.15 -40.7% -33.4 Open Sep 10, 2026
VRCA Verrica Pharmaceuticals Spec buy $5.69 $3.14 -44.8% -34.3 Open Aug 28, 2026
ARVN Arvinas Spec buy $10.78 $8.14 -24.5% -34.6 Closed Jun 23, 2026 May 4, 2026
SRPT Sarepta Therapeutics Spec buy $17.79 $14.77 -17% -35.2 Open Feb 13, 2026
QNRX Quoin Pharmaceuticals Spec buy $6.22 $3.36 -46% -35.4 Open Aug 31, 2026
ELTX Elicio Therapeutics Avoid $2.76 $3.85 +39.5% -35.6 Closed Jun 18, 2026 Jun 16, 2026
CGEM Cullinan Therapeutics Buy▵ $12.57 $9.28 -26.2% -36.6 Open Jan 22, 2026
NTLA Intellia Therapeutics Spec buy▵ $13.20 $9.78 -25.9% -36.7 Open Apr 28, 2026
JANX Janux Therapeutics Buy $14.11 $10.71 -24.1% -36.8 Open Apr 29, 2026
ACRS Aclaris Therapeutics Buy $4.47 $3.38 -24.4% -37.1 Closed Nov 17, 2026 Apr 29, 2026
ANAB AnaptysBio Spec buy $65.58 $45.61 -30.5% -38.1 Open May 12, 2026
CCCC C4 Therapeutics Buy▵ $3.68 $2.53 -31.3% -38.2 Open May 13, 2026
ADAG Adagene Spec buy $1.84 $1.48 -19.6% -39.1 Open Jan 2, 2026
AUTL Autolus Therapeutics Spec buy $1.95 $1.09 -44.1% -39.8 Open Aug 4, 2026
IMMX Immix Biopharma Buy $10.66 $7.20 -32.5% -40.1 Open May 12, 2026
XENE Xenon Pharmaceuticals Buy $57.40 $38.78 -32.4% -41.3 Open May 4, 2026
GERN Geron Spec buy $1.57 $0.95 -39.5% -41.6 Closed Oct 29, 2026 Aug 6, 2026
SANA Sana Biotechnology Spec buy $3.26 $2.37 -27.3% -41.7 Closed Nov 6, 2026 Apr 27, 2026
RCUS Arcus Biosciences Buy▵ $24.69 $16.39 -33.6% -42.5 Open Jun 4, 2026
VKTX Viking Therapeutics Buy $36.41 $26.88 -26.2% -42.5 Open Dec 23, 2025
ACRV Acrivon Therapeutics Buy $1.93 $1.43 -25.9% -43.3 Open Jan 8, 2026
SNDX Syndax Pharmaceuticals Buy $20.56 $9.20 -55.3% -43.9 Open Sep 4, 2026
MPLT MapLight Therapeutics Spec buy $12.92 $6.57 -49.1% -44.1 Open Aug 5, 2026
TSHA Taysha Gene Therapies Buy $6.46 $4.00 -38.1% -47.3 Open Apr 27, 2026
GRCE Grace Therapeutics Spec buy▵ $3.83 $2.16 -43.6% -47.7 Closed Apr 27, 2026 Jan 26, 2026
IPSC Century Therapeutics Spec buy $2.21 $1.37 -38% -48.6 Open Jun 9, 2026
ZNTL Zentalis Pharmaceuticals Buy▵ $3.83 $1.49 -61% -48.7 Open Aug 21, 2026
RCKT Rocket Pharmaceuticals Spec buy $3.59 $2.11 -41.2% -49 Open May 11, 2026
SMMT Summit Therapeutics Buy $15.94 $10.67 -33.1% -49.5 Open Feb 20, 2026
CNTB Connect Biopharma Spec buy $2.54 $1.24 -51.2% -49.5 Closed Sep 16, 2026 Aug 13, 2026
CHRS Coherus Oncology Spec buy $1.26 $0.64 -49.3% -49.7 Closed Nov 10, 2026 Aug 6, 2026
NBP NovaBridge Biosciences Spec buy $1.95 $0.82 -57.8% -49.7 Open Jun 30, 2026
DBVT DBV Technologies Buy $20.27 $14.70 -27.5% -50 Closed Jul 17, 2026 Dec 22, 2025
KPRX Kiora Pharmaceuticals Spec buy $2.32 $1.56 -32.8% -50 Closed Oct 30, 2026 Apr 27, 2026
AGMB Agomab Therapeutics Spec buy $12.68 $5.92 -53.3% -50.4 Open Jun 24, 2026
AKBA Akebia Therapeutics Spec buy $1.16 $0.70 -40% -51.2 Closed Oct 15, 2026 May 8, 2026
CYDY CytoDyn Spec buy $0.32 $0.22 -31.2% -54.1 Closed Sep 1, 2026 Apr 27, 2026
ALLO Allogene Therapeutics Spec buy $1.79 $0.74 -58.7% -54.2 Open Jul 16, 2026
CLNN Clene Buy▵ $5.18 $3.22 -37.8% -55.1 Open Jan 12, 2026
GLUE Monte Rosa Therapeutics Buy $17.50 $9.07 -48.2% -55.2 Open Apr 14, 2026
CGTX Cognition Therapeutics Spec buy $1.08 $0.69 -36.4% -56.1 Closed Nov 6, 2026 Mar 9, 2026
KYTX Kyverna Therapeutics Buy▵ $8.99 $4.70 -47.7% -56.9 Open Apr 27, 2026
KTTA Pasithea Therapeutics Buy $0.77 $0.43 -43.6% -57.4 Open May 18, 2026
LRMR Larimar Therapeutics Buy $5.23 $2.99 -42.8% -57.6 Open Mar 2, 2026
OCGN Ocugen Spec buy $1.65 $1.00 -39.4% -58 Closed Sep 24, 2026 Jan 22, 2026
NGEN NervGen Pharma Spec buy $3.85 $1.96 -49.1% -58.3 Open Apr 27, 2026
IMTX Immatics Buy $10.45 $6.29 -39.8% -59.4 Open Jan 2, 2026
MDNAF Medicenna Therapeutics Spec buy $0.32 $0.16 -50.3%* -59.4 Closed Nov 18, 2026 May 26, 2026
INAB IN8bio Spec buy $1.56 $0.98 -37.2% -60.4 Closed Aug 7, 2026 Jun 2, 2026
ARTV Artiva Biotherapeutics Spec buy $7.27 $4.28 -41.2% -61.1 Closed Oct 28, 2026 Jun 9, 2026
BBOT BridgeBio Oncology Therapeutics Spec buy $6.75 $1.94 -71.3% -62.4 Open Sep 9, 2026
IMRX Immuneering Spec buy▵ $6.66 $3.46 -48% -65.8 Open Dec 29, 2025
VTVT vTv Therapeutics Spec buy $36.41 $17.29 -52.5% -68.5 Open Feb 4, 2026
GANX Gain Therapeutics Buy▵ $3.19 $1.71 -46.4% -69 Closed Oct 2, 2026 Dec 22, 2025
GPCR Structure Therapeutics Buy $43.56 $18.17 -58.3% -69.1 Open Apr 28, 2026
ATHE Alterity Therapeutics Buy $4.73 $1.87 -60.5% -71.9 Open May 1, 2026
ADCT ADC Therapeutics Avoid $1.01 $1.73 +71.3% -73.6 Closed Oct 9, 2026 Aug 14, 2026
CTMX CytomX Therapeutics Spec buy $4.46 $1.94 -56.5% -75.9 Open Mar 23, 2026
CRBU Caribou Biosciences Spec buy $1.94 $0.62 -68.2% -79.7 Closed Oct 7, 2026 May 8, 2026
CABA Cabaletta Bio Buy▵ $3.31 $1.02 -69.2% -80.3 Open May 15, 2026
BIOA BioAge Labs Buy $15.34 $5.10 -66.8% -80.5 Open May 18, 2026
CATX Perspective Therapeutics Buy▵ $2.73 $1.21 -55.7% -80.9 Closed Oct 26, 2026 Jan 5, 2026
PMN ProMIS Neurosciences Spec buy $14.06 $3.00 -78.7% -81.5 Closed Nov 2, 2026 Jul 29, 2026
LXEO Lexeo Therapeutics Spec buy $8.12 $2.85 -64.8% -82.1 Open Jan 12, 2026
STRO Sutro Biopharma Buy▵ $33.59 $8.92 -73.4% -82.6 Open Apr 27, 2026
TARA Protara Therapeutics Spec buy $7.43 $2.32 -68.8% -83.2 Open Feb 23, 2026
ALT Altimmune Buy▵ $4.09 $1.53 -62.6% -83.5 Open Jan 5, 2026
ERAS Erasca Avoid $9.11 $19.50 +114.1% -93.5 Closed Jul 14, 2026 Apr 29, 2026
WVE Wave Life Sciences Buy▵ $13.44 $2.84 -78.9% -96.5 Open Mar 3, 2026
CUE Cue Biopharma Spec buy $26.91 $2.83 -89.5% -101.4 Open Jun 3, 2026
MIST Milestone Pharmaceuticals Buy $2.20 $0.36 -83.4% -103.5 Closed Nov 16, 2026 Dec 16, 2025
EYPT EyePoint Buy $13.34 $0.41 -96.9% -114.4 Closed Oct 20, 2026 May 1, 2026
GUTS Fractyl Health Spec buy $25.08 $0.90 -96.4% -115.5 Closed Nov 13, 2026 Jan 7, 2026
ABOS Acumen Pharmaceuticals Spec buy▵ $2.71 $0.24 -91.1% -116.2 Closed Nov 2, 2026 Mar 23, 2026
QURE uniQure Avoid $17.99 $46.29 +157.3% -146.6 Closed Jun 18, 2026 Mar 9, 2026
REPL Replimune Group Avoid $1.70 $9.00 +429.4% -428.3 Closed Jun 1, 2026 Apr 13, 2026

On BD's watch list

  • Prime has the best clinical evidence in gene editing but no issued patents, a going-concern note, $168M of non-cancellable rent, and prices in vivo liver prime editing working on one dosed patient and a mouse — wait for a human pharmacodynamic datapoint or a materially lower price.

  • Interim was blinded and uninformative on efficacy, but faster-than-expected enrollment pulls the real binary into 2027; drug is near cash value but reverse split and post-topline raise both look likely, so it stays on the watch list rather than a buy.

    Latest note · Nov 17, 2026 ↗ · watching since Sep 9, 2026
  • The Lilly supply deal puts the CDK4/6 combination on the calendar and cash came in ahead of estimate, but no patient neutrophil data exist and the Incyte option decision remains pending, so the watch stance is unchanged.

    Latest note · Nov 17, 2026 ↗ · watching since Oct 2, 2026
  • Longer follow-up shows rinzimetostat's landmark rPFS fell from 84% to 59%, matching but not beating mevrometostat, upgrade criteria not met, and value now depends almost entirely on Pfizer's February readout.

    Latest note · Nov 17, 2026 ↗ · watching since Nov 4, 2026
  • FDA alignment on a NEC registrational path widens the IDE849 market but rests on 7 confirmed responders from 19 Chinese patients; Western efficacy data still not public and spending commitments are growing ahead of the data.

    Latest note · Nov 17, 2026 ↗ · watching since Sep 14, 2026
  • GNLX Genelux Watch

    With share count up 26% YTD, accrued trial bills doubled, working capital cushion thin, and OnPrime topline due within weeks, waiting for the data and the financing that follows is more defensible than guessing ahead of the print.

    Latest note · Nov 17, 2026 ↗ · watching since Jul 15, 2026
  • Pramipexole's antidepressant effect is well-validated but at ~$1.1B EV the stock already prices a likely PACE-1 win, ALTO-207's own data are thin (32 patients, single-blind, secondary endpoint), and the moat around two generic drugs rests on method claims expiring ~2038-2039 with no NCE exclusivity.

  • At ~$2.4B EV the stock already prices a Phase 3 win; canvuparatide has not been shown to beat Yorvipath on anything but injection frequency, there is no issued U.S. patent, and the obesity leg has no interpretable data yet.

  • Runway into Q3 2028 reaffirmed and burn partly explained by prepayments, but ZENITH AD-2 redesign as a TCS-combination trial removes naïve monotherapy replication; a small starter position remains reasonable ahead of Q1 2027 durability data.

    Latest note · Nov 14, 2026 ↗ · watching since Jun 6, 2026
  • CMC appears on track for a year-end IND, but first progressions to muscle-invasive disease, a drifting BCG-unresponsive 12-month CR, a pivoting IR cohort, and contradictory funding language keep the Watch stance intact with no reason to hurry.

    Latest note · Nov 13, 2026 ↗ · watching since Jun 23, 2026
  • The predicted equity raise arrived via a new $100M ATM, Hologen's $95M remains unpaid, and none of the three stated upgrade triggers (Hologen payment, AQUAx2 readout, sub-$9 print) has fired, so the watch stance is maintained.

    Latest note · Nov 13, 2026 ↗ · watching since Sep 8, 2026
  • HUNT1 acquisition adds cheap optionality but runway slipped a quarter to Q2 2028 and Lineage now has a second program whose trial timeline it doesn't control; the Roche OpRegen controlled-trial trigger remains the only event that re-rates the stock.

    Latest note · Nov 13, 2026 ↗ · watching since Aug 17, 2026
  • First ATM draw of $68.9M at ~$100/share improves the treasury with minimal dilution, but ALTO's primary endpoint was lowered to non-inferiority and the AI-guided dosing label risk is new; hold house money into PEAK as the cleanest remaining IL-6 test.

    Latest note · Nov 13, 2026 ↗ · watching since Jan 29, 2026
  • Q3 cash burn of ~$56.7M passed the $60M test and ATM issuance paused, keeping both 4FRONT readouts funded from cash, but expense run-rate remains ~$68M with 4SIGHT costs only beginning; patient capital might consider a small position at ~$12 sized to a non-inferiority coin flip.

    Latest note · Nov 13, 2026 ↗ · watching since Jul 3, 2026
  • LEGACY's Q4 start is now formally contingent on financing, cash has fallen to $69.7M with $20.7M in committed manufacturing obligations, and a $150M raise at current prices implies ~53% dilution — the raise remains the event to engage around, not ahead of.

    Latest note · Nov 13, 2026 ↗ · watching since Aug 14, 2026
  • Melanoma interim slipped to 1H 2027 and reframed as a futility test, but extended runway now reaches past the readout, reducing forced-raise risk; trigger reset but still unfired.

    Latest note · Nov 13, 2026 ↗ · watching since Aug 5, 2026
  • ALMS Alumis Watch

    Envu is an approvable, royalty-free, top-tier oral psoriasis drug at a reasonable EV, but the going-concern qualification, near-certain dilutive raise of 30-40%, fourth-to-market BID positioning, and failed lupus trial make it not cheap enough to own the financing.

  • At ~$306M EV the stock is roughly fairly priced for two binary assets with no dated readout on the lead; FURVENT missed on a comparator anomaly rather than drug failure, but ALPACCA faces the same measurement risk against stronger comparators and ARR-217's confirmed response rate needs validation in a larger, more mature cohort.

  • Verekitug has two positive Phase 2s at near-zero enterprise value, but the Phase 3 appears mis-specified for a broad label, uses an untested dose, faces longer-acting competitors already in Phase 3, and requires a certain large dilutive financing before any data.

  • The resubmission remains on track but the CNPV will expire unused, eliminating the vaping program's only accelerant; the two core unresolved questions (Sopharma arbitration, NCE exclusivity) remain open.

    Latest note · Nov 11, 2026 ↗ · watching since Aug 12, 2026
  • First patient dosed and balance sheet intact, but the dose bridge remains unproven, a new single-source WuXi API supply risk emerged ahead of the December BIOSECURE list deadline, and the lower EV improves entry math without improving the drug's odds.

    Latest note · Nov 11, 2026 ↗ · watching since Aug 6, 2026
  • The ARDS readout has slipped a second time to 2H2027, cash is down to $7.5M with a raise now explicitly on the table, and the endpoint has shifted from survival to ECMO prevention; the science hasn't worsened but the structure has, keeping the stock on watch with no new buying until a U.S. patient is dosed, FDA aligns on the adaptive design, and a raise clears.

    Latest note · Nov 11, 2026 ↗ · watching since Jun 13, 2026
  • FDA feedback was better than feared with a workable 300-patient brain-metastasis Phase 3 and accelerated-approval path, but the trial remains unfunded with no partner announced and the company has disclosed it needs substantial additional capital.

    Latest note · Nov 11, 2026 ↗ · watching since Oct 8, 2026
  • Q3 earnings quality improved with 33% operating margin and guidance raised to ~$1B, but U.S. sales flattened sequentially, a new tariff emerged, and the valuation has stretched to ~10x sales ahead of the SubQ readout.

    Latest note · Nov 10, 2026 ↗ · watching since Jun 3, 2026
  • Q1 2027 readout remains on schedule but the stock is now ~11% above the probability-weighted fair value and near its 52-week high, with insiders and smart money selling into strength, making the watch stance unchanged.

    Latest note · Nov 10, 2026 ↗ · watching since Nov 6, 2026
  • Transform-HTN confirms durable blood-pressure effect and manageable potassium at 48 weeks, but hyponatremia remains undisclosed, the withdrawal sub-study is unreported, and the core commercial problem — second to market against AstraZeneca with a generic payer wall — is unchanged.

    Latest note · Nov 10, 2026 ↗ · watching since Oct 20, 2026
  • HORIZON enrollment to 50+ patients improves the quality of the coming binary readout but provides no new efficacy data; at ~$35 and ~$1.7B EV the stock has moved above the probability-weighted value with no new evidence, so the WATCH stance is maintained pending the non-FSGS cohort clearing ≥30% uACR with uPCR disclosed.

    Latest note · Nov 10, 2026 ↗ · watching since Nov 3, 2026
  • MAIA-ovarian fully enrolled with Q1 2027 readout locked, cash floor intact at ~$85M EV, but 'totality of the data' wording raises goalpost concerns and the core tension from June remains unchanged.

    Latest note · Nov 10, 2026 ↗ · watching since Jun 4, 2026
  • CAMP4 has a genuinely novel upregulation platform in an unmet disease but zero human data, no issued patents, no US sites, no PD biomarker, and the nearest class precedent just failed Phase 3; at $4.06 the stock prices roughly fair odds on a 2028 coin flip.

  • FORTIFI-HN01 cleared enrollment gate on schedule and valuation has compressed to ~$240M enterprise value, but burn strains runway, WuXi Biologics BIOSECURE exposure was underweighted, and efficacy remains single-arm until mid-2027.

    Latest note · Nov 10, 2026 ↗ · watching since May 30, 2026
  • IND cleared on schedule and cash covers all 2027 readouts, but no PV patient has been dosed and the scientific case is unchanged; maintain Watch until PV Part 1 data demonstrate hematocrit control without a platelet problem.

    Latest note · Nov 10, 2026 ↗ · watching since Oct 27, 2026
  • ANNX Annexon Watch

    ANX1502 sidelined to formulation lab and GBS BLA still needs FDA alignment, but ARCHER II trial execution remains clean and balance sheet is adequate into 2028.

    Latest note · Nov 10, 2026 ↗ · watching since Feb 27, 2026
  • RAP-219 has a validated mechanism and ample cash but the epilepsy case rests on an uncontrolled 30-patient study, the only randomized result is a marginal p=0.045 with twice the dropouts on drug, and the next efficacy readout is ~two years away.

  • VY1706 dosing slipped from Q4 2026 to 'next few months,' a September layoff appeared only in the 10-Q, ATM selling at lower prices, and stock trades ~$25M below cash; proxy waiting game still better played after the data.

    Latest note · Nov 6, 2026 ↗ · watching since Mar 17, 2026
  • APEX dated to end of January 2027 with ~$153M EV over cash creating asymmetric setup on paper, and AZD5462 LUMINARA mildly supportive of RXFP1 mechanism, but bear case (relaxin history, CADENCE 6MWD flatline, WuXi sole-sourcing) unchanged; small position may warrant sizing for binary-event tolerant readers but watch-list stance maintained for everyone else.

    Latest note · Nov 6, 2026 ↗ · watching since Jun 9, 2026
  • The stock is back at roughly half of net cash with both Phase 1 gates cleared and real kidney expertise on staff, but an ~$8M quarterly burn strains the 2029 runway, a financing toolkit (shelf + ATM) signals likely dilution before the Q4 2027 binary, and the mechanism remains unproven in a human kidney.

    Latest note · Nov 6, 2026 ↗ · watching since Jun 24, 2026
  • Q3 cash of $403.8M and NOVA-2 on track pass two of three thesis checks, but a newly disclosed $200M ATM introduces a soft ceiling on pre-data rallies without yet tripping the PASS trigger; the SPECULATIVE BUY entry level remains ~$32.

    Latest note · Nov 6, 2026 ↗ · watching since Oct 30, 2026
  • Keros passed capital-allocation tests (buyback executed, ATM unused) but the preclinical burn mix is unchanged and no upgrade trigger (positive RENEW or meaningful capital-return commitment) has fired.

    Latest note · Nov 6, 2026 ↗ · watching since Oct 7, 2026
  • Q3 shows $16.3M cash with runway only to Q3 2027, the Australian rebate bridge is gone, the BLA date has slipped again, and the confirmatory trial has dropped off the milestone calendar, but the February MHRA filing date held and the voucher thesis remains intact, keeping the watch stance with a negative tilt.

    Latest note · Nov 6, 2026 ↗ · watching since Jul 21, 2026
  • STRATUS-HCM delivers the placebo-controlled design with separate cohorts and objective peak VO2 primary endpoint the author asked for, but trough gradient question remains open, nHCM has no Phase 2 VO2 data, and at ~$2.62B EV the price trigger of $25–27 has not been met.

    Latest note · Nov 6, 2026 ↗ · watching since Sep 30, 2026
  • Record Q3 thalassemia revenue of $48.7M and 75% six-month persistence strengthen the launch floor, but the SCD leg is unchanged — a REMS still looks likely, HIBISCUS reports before the February 1 label, and the voxelotor precedent remains; waiting for ASH and February 1 is still the sensible course.

    Latest note · Nov 6, 2026 ↗ · watching since Oct 16, 2026
  • A going-concern warning, ADI-212 enrollment slip, and stock at ~$2.92 (deeply below $100.9M cash) make any equity raise severely dilutive; the science is unchanged but the financing gap is now the dominant risk, and the patient approach is to wait for the company to price its deal before stepping in.

    Latest note · Nov 6, 2026 ↗ · watching since Aug 7, 2026
  • K2 covenant terms failed the 'benign' gate, locking up ~$60M from October 2027 and making a pre-topline equity raise likely, while valuation has drifted higher without any improvement in the probability of success; enrollment close remains the key remaining gate.

    Latest note · Nov 5, 2026 ↗ · watching since Oct 9, 2026
  • No new clinical data and a ~$4.0B market cap still pricing in a Phase 3 win on open-label numbers; the key vascular anomaly catalyst is now dated for Dec 14, warranting continued watch until confirmed, durable responses at expansion doses are shown.

    Latest note · Nov 5, 2026 ↗ · watching since Aug 10, 2026
  • Q3 10-Q confirms no ATM sales and cash on plan, but PIKture-01 data remain absent and manufacturing is single-sourced in China, so the watch stance is maintained pending year-end data.

    Latest note · Nov 5, 2026 ↗ · watching since Oct 23, 2026
  • Q3 cash held at $643.1M with ATM undrawn, but the UK launch slipped to 2027, a new MFN pricing risk disclosure suggests European prices could cap U.S. upside, and the PREVAIL DSMB recommendation remains the sole binary with no U.S. NDA date in sight.

    Latest note · Nov 5, 2026 ↗ · watching since Aug 4, 2026
  • Tranche 4 lapsed and IZAR-2 slipped to Q1 2027, worsening the clock, but valuation improved materially; the real de-risking event (HS label efficacy table content) has moved to 2027.

    Latest note · Nov 5, 2026 ↗ · watching since Aug 11, 2026
  • BP-205 MAD data passed safety checks but showed no efficacy signal, the Delaware ruling is now pushed to February 2027, growth slowed to 12%, and royalties are taking a larger share of revenue — the binary remains unresolved.

    Latest note · Nov 5, 2026 ↗ · watching since Sep 11, 2026
  • Well-engineered LPA1 antagonist with validated class and funded Phase 2, but PIPE-791 has never been tested in IPF patients, its differentiation claim met a bad data point in Bristol's 120 mg arm, the FDA's blood-pressure concern has kept PROPEL-IPF out of the US, and all patents are pending.

  • Q3 headline beat was driven by a one-time CareMed stocking order masking flat underlying ORLADEYO revenue, adult capsule volume is already slipping, and neither de-risking trigger for an upgrade has fired.

    Latest note · Nov 5, 2026 ↗ · watching since Sep 16, 2026
  • Runway extended to Q1 2028 on lean burn, but the hsCRP readout slipped to H1 2027 and VacSYn's missing biomarker numbers remain unreported, leaving 2026 with no quantified efficacy-adjacent result on any owned asset.

    Latest note · Nov 5, 2026 ↗ · watching since Jun 1, 2026
  • The plenary added lower-GI and large-polyp data and a strategically credentialed new chair, but the FDA registrational-path endpoint — the single fact that determines REC-4881's value and filing timeline versus the April 2029 patent expiry — has slipped to 'later this year', leaving the watch stance unchanged.

    Latest note · Nov 3, 2026 ↗ · watching since Sep 23, 2026
  • Zero EMPEROR discontinuations and minimal ATM use are positive, but accelerating burn reduces cash at the Q3 2027 readout and makes a pre-data raise more likely, so patience until 1H 2027 checkpoints remains warranted.

    Latest note · Oct 30, 2026 ↗ · watching since Oct 22, 2026
  • INSM Insmed Watch

    Q3 beat validates the launch curve and collapses the financing bear case, but net-versus-gross patient adds remain undisclosed and TPIP data has drifted later, so the upgrade trigger has not yet fired.

    Latest note · Oct 30, 2026 ↗ · watching since Aug 13, 2026
  • The Duravelo-2 randomized data readout has slipped a year to 2H 2027, removing the near-term re-rating catalyst; burn is improving but no capital-allocation event has occurred, so the watch stance is maintained with no new reason to step in.

    Latest note · Oct 30, 2026 ↗ · watching since Oct 5, 2026
  • Relcobatinib has a winnable Phase 3 but ENABLE-2 is designed to beat generic 2G TKIs rather than asciminib or MK-4208, and at $41.93 the stock already prices a successful 2L+ franchise plus much of a first-line future that has no trial yet.

  • Telix's profitable gallium imaging franchise lacks durable patent protection and is funding an unproven therapeutics strategy via dilutive M&A; wait for the ITM vote, pricing data against new competition, and BiPASS readout before owning it.

  • ADPKD program gains a more credible regulatory endpoint (htTKV) and a seasoned CMO, but its readout slipped to 1H 2029 past the funded runway, and the lead Alport asset's efficacy case is still n=3 on an unvalidated surrogate.

    Latest note · Oct 20, 2026 ↗ · watching since Jun 18, 2026
  • ABVX Abivax Watch

    Strong Phase 3 efficacy but all six malignancies on the 50 mg dose and a label decision a year away make the current ~$6.2B EV insufficient discount to buy.

  • Cohort 5 produced only one stable-disease result (not an objective response) and no DLTs, modestly de-risking safety but leaving efficacy and pharmacodynamics unproven; Watch List maintained pending RECIST-confirmed responses with denominators.

    Latest note · Oct 6, 2026 ↗ · watching since Jul 31, 2026
  • QTTB Q32 Bio Watch

    EADV delivered the JAK-naive/experienced split (mechanistically coherent) but the ITT mean remains withheld and responder-counting questions go unanswered, leaving the author short of speculative-buy conviction despite the enterprise value collapsing to ~$12M.

    Latest note · Sep 30, 2026 ↗ · watching since Sep 21, 2026
  • RA Capital's $200M add and Paradigm's new 5.8% stake confirm specialist money read the 57% CR as a dosing problem not a drug failure, strengthening the ownership leg of the thesis, but efficacy at 70 mg remains the only thing that can convert the rating.

    Latest note · Sep 17, 2026 ↗ · watching since Jun 11, 2026
  • Pharmacodynamics are genuinely interesting but every efficacy number comes from six unblinded patients on an active backbone with one ineligible patient providing the only complete response; a control arm is needed before taking a position.

  • Despite a de-risked mechanism and strong balance sheet post-financing, the 21-patient efficacy signal, untested Phase 3 dose, primary endpoint outside FDA's qualified 24-month context of use, and 85% post-financing markup into a 26-month catalyst desert make this the wrong entry at the wrong price.

The full record

Category# callsBeat XBIAvg returnAvg vs XBI
Open buy calls 122 26% -9.9% -15
Core 64 27% -4.8% -13.4
Speculative 58 26% -15.6% -16.8
Open avoid calls 51 75% — +24.8
Closed buy calls 44 14% -20.5% -33.7
Closed avoids 22 59% — -15.8

2 published calls are held back from this session's figures, so the counts above are short by 2: MDNAF — its entry session has not traded yet; SLS — its entry session has not traded yet. Nothing has been removed from the record — each returns as soon as it can be priced honestly.

⚡ Get these calls the day I publish them. Biotech Distilled · $25/mo · $250/yr · Distilled Pro $300/yr
Subscribe on Substack →

Hypothetical editorial track record, not a managed portfolio — past performance does not guarantee future results. Not investment advice.